These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 29395100)

  • 21. Statin intolerance in heterozygous familial hypercolesterolemia with cardiovascular disease: After PCSK-9 antibodies what else?
    Sbrana F; Dal Pino B; Bigazzi F; Ripoli A; Passino C; Gabutti A; Pasanisi EM; Petersen C; Valleggi A; Todiere G; Barison A; Giannoni A; Panchetti L; Becherini F; Pianelli M; Luciani R; Sampietro T
    Eur J Prev Cardiol; 2017 Sep; 24(14):1528-1531. PubMed ID: 28555526
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of Statin Therapy and Dose on Cardiovascular and Limb Outcomes in Peripheral Arterial Disease: A Systematic Review and Meta-analysis.
    Sofat S; Chen X; Chowdhury MM; Coughlin PA
    Eur J Vasc Endovasc Surg; 2021 Sep; 62(3):450-461. PubMed ID: 34389230
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Collective impact of conventional cardiovascular risk factors and coronary calcium score on clinical outcomes with or without statin therapy: The St Francis Heart Study.
    Waheed S; Pollack S; Roth M; Reichek N; Guerci A; Cao JJ
    Atherosclerosis; 2016 Dec; 255():193-199. PubMed ID: 27693004
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Utilization of lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients at high and very-high cardiovascular risk: Real-world evidence from Germany.
    März W; Dippel FW; Theobald K; Gorcyca K; Iorga ŞR; Ansell D
    Atherosclerosis; 2018 Jan; 268():99-107. PubMed ID: 29197254
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adding Alirocumab to Rosuvastatin Helps Reduce the Vulnerability of Thin-Cap Fibroatheroma: An ALTAIR Trial Report.
    Sugizaki Y; Otake H; Kawamori H; Toba T; Nagano Y; Tsukiyama Y; Yanaka KI; Yamamoto H; Nagasawa A; Onishi H; Takeshige R; Nakano S; Matsuoka Y; Tanimura K; Takahashi Y; Fukuyama Y; Shinke T; Ishida T; Hirata KI
    JACC Cardiovasc Imaging; 2020 Jun; 13(6):1452-1454. PubMed ID: 32199850
    [No Abstract]   [Full Text] [Related]  

  • 26. Characteristics and Cardiovascular Disease Event Rates among African Americans and Whites Who Meet the Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER) Trial Inclusion Criteria.
    Colantonio LD; Monda KL; Rosenson RS; Brown TM; Mues KE; Howard G; Safford MM; Yedigarova L; Farkouh ME; Muntner P
    Cardiovasc Drugs Ther; 2019 Apr; 33(2):189-199. PubMed ID: 30746585
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ezetimibe + statin: insufficient benefit.
    Prescrire Int; 2016 Oct; 25(175):245-246. PubMed ID: 30645833
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Statins.
    Ratchford EV; Martin SS
    Vasc Med; 2017 Oct; 22(5):442-445. PubMed ID: 28803537
    [No Abstract]   [Full Text] [Related]  

  • 29. Managing the dyslipidemia of metabolic syndrome: beyond statin therapy.
    Jialal I; Smith G
    Metab Syndr Relat Disord; 2012 Jun; 10(3):159-60. PubMed ID: 22568574
    [No Abstract]   [Full Text] [Related]  

  • 30. PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab.
    Blom DJ; Dent R; Castro RC; Toth PP
    Vasc Health Risk Manag; 2016; 12():185-97. PubMed ID: 27274264
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Perceptions of Canadian Vascular Surgeons Toward Pharmacologic Risk Reduction in Patients with Peripheral Artery Disease: 2018 Update.
    Li B; Salata K; de Mestral C; Hussain MA; Aljabri BA; Lindsay TF; Verma S; Al-Omran M
    Ann Vasc Surg; 2019 Jul; 58():166-173.e4. PubMed ID: 30771465
    [TBL] [Abstract][Full Text] [Related]  

  • 32. LDL cholesterol: How low to go?
    Packard CJ
    Trends Cardiovasc Med; 2018 Jul; 28(5):348-354. PubMed ID: 29336946
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Available oral lipid-lowering agents could bring most high-risk patients to target: an estimate based on the Dyslipidemia International Study II-Italy.
    De Ferrari GM; Perna GP; Nicosia A; Guasti L; Casu G; Cuccia C; Picco F; Strazzella C; Totaro R; Cercone S; Canullo L; Horack M; Lautsch D; Gitt AK; Di Biase M
    J Cardiovasc Med (Hagerstown); 2018 Sep; 19(9):485-490. PubMed ID: 29917002
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lipid lowering drug therapy in patients with coronary heart disease from 24 European countries--Findings from the EUROASPIRE IV survey.
    Reiner Ž; De Backer G; Fras Z; Kotseva K; Tokgözoglu L; Wood D; De Bacquer D;
    Atherosclerosis; 2016 Mar; 246():243-50. PubMed ID: 26812002
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Personalized absolute benefit of statin treatment for primary or secondary prevention of vascular disease in individual elderly patients.
    Stam-Slob MC; Visseren FL; Wouter Jukema J; van der Graaf Y; Poulter NR; Gupta A; Sattar N; Macfarlane PW; Kearney PM; de Craen AJ; Trompet S
    Clin Res Cardiol; 2017 Jan; 106(1):58-68. PubMed ID: 27554244
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Trust the Blinded Randomized Evidence That Statin Therapy Rarely Causes Symptomatic Side Effects.
    Peto R; Collins R
    Circulation; 2018 Oct; 138(15):1499-1501. PubMed ID: 30354509
    [No Abstract]   [Full Text] [Related]  

  • 37. MY APPROACH to the Patient With Memory Loss Who Needs a Statin.
    Watson KE; Sallam T
    Trends Cardiovasc Med; 2017 Feb; 27(2):158-159. PubMed ID: 28107839
    [No Abstract]   [Full Text] [Related]  

  • 38. Statin therapy for young adults: A long-term investment worth considering.
    Miedema MD; Nauffal VD; Singh A; Blankstein R
    Trends Cardiovasc Med; 2020 Jan; 30(1):48-53. PubMed ID: 30808553
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of statins on atherosclerotic plaque.
    Almeida SO; Budoff M
    Trends Cardiovasc Med; 2019 Nov; 29(8):451-455. PubMed ID: 30642643
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pleiotropic Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitors?
    Bittner V
    Circulation; 2016 Nov; 134(22):1695-1696. PubMed ID: 27895023
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.